AstraZeneca SWOT & PESTLE Analysis
COMPANY PROFILE -AstraZeneca
Business Sector :Biopharmaceutical and Pharmaceutical
Operating Geography :United Kingdom, Europe, Global
About AstraZeneca :
AstraZeneca is an Anglo-Swedish global pharmaceutical and biopharmaceutical company with headquarter in Cambridge, United Kingdom. The business is driven and led by science, technology and innovation, providing medicines used by millions of patients worldwide. The Swedish Astra AB and the British Zeneca Group were combined to form the company, which was established in 1999. It has been one of the largest pharmaceutical companies in the world since the merger and has made a number of business acquisitions, including Cambridge Antibody Technology in 2006, MedImmune in 2007, Spirogen in 2013, and Definiens in 2014. Three strategic locations host the majority of its research and development activities: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, United States. It has a market cap of $204.37 Billion as in July, 2022. The product portfolio on the group consists of medicines for curing diseases such as Cancer, Cardio vascular, Respiratory, Neuroscience, Oncology, Infection and Vaccines. AstraZeneca was awarded Company of the year 2020 by Scrip. In May 2022, AstraZeneca and RQ Biotechnology Ltd. (RQ Bio) entered into a licence agreement for a portfolio of early-stage monoclonal antibodies (mAbs) directed against COVID-19-causing SARS-CoV-2. According to the agreement, AstraZeneca has been granted the sole right to create, produce, and market mAbs that are effective against SARS-CoV-2.
The USP of AstraZeneca lies in it being under the Top 10 pharmaceutical companies in the world. AstraZeneca’s mission as per their website is to “turn ideas into life-changing medicines that improve patients’ lives and benefit society.”
AstraZeneca Revenue :
$ 37.42 Billion - FY ending 31st December 2021
$ 26.62 Billion - FY ending 31st December 2020
Competitive Analysis of AstraZeneca
1. Ranked first in innovation index. 2. High percentage of R&D Expenditure amongst the industry leaders. 3. Strong financial performance. | 1. Bad public relations image and other controversies 2. High failure rate for drug leads to high operational losses. 3. Problems of blood clots with their COVID-19 vaccine |
1. Vast growth opportunities in the emerging markets that can be future drivers for growth. | 1. Acquisition by financially bigger and wealthier companies. 2. Loss of revenue because of generics. 3. High drug development cost. |
Complete Report
USD 12.53
- Debit/Credit card
- PayPal

Detailed SWOT Analysis of AstraZeneca
Strength
1. Ranked first in the Innovation Index: In 2018 AstraZeneca topped the Pharmaceutical Innovation Index released by IDEA pharma for the first time leading behind industry leaders such as Johnson&Johnson, Pfizer, Abbot, Novartis, Bayer, Sanofi, Glaxo Smith Kline and many others, AstraZeneca topped the ranking even though they were ranked on the 15th spot in 2017, this comes on the back of some key strategic decisions taken by the management at AstraZeneca that helped to pipeline the positive data and ideas and stem the company’s downward trend because of the loss of several exclusive products between the year 2011 and 2017. AstraZeneca was considerably behind in developing cancer immunotherapy drugs which the market leaders such as Merck, Roche and Bristol-Myers were also competing for but the successful test trials by AstraZeneca could give it a major advantage. The main reason that AstraZeneca topped the Pharmaceutical Innovation Index in 2018 from the 15th position was the launch of five new significant medicines in 2017 primarily across their therapy areas which are no mean feat for a company in the industry. Astrazeneca dropped two spots from the 6th rank in 2019, to the 8th rank in 2021. In 2020, Astrazeneca ranked 1st in the Invention Index due to their COVID-19 research and efforts.
2. High percentage of R&D expenditure amongst the industry leaders: In absolute spending on R&D AstraZeneca ranks at the 6th spot overall in the pharmaceutical industry in Financial Year 2017 despite being much smaller in size in terms of revenue than some of its competitors, it outperforms Bristol-Myers Squibb, Sanofi and GlaxoSmithKline all of which have a higher revenue than AstraZeneca, this comes on the back of a decline in revenue in 2017 by more than 2% than that in 2016, but the company showed positive results in the Q4 of FY 2017 where its revenue grew by 3% than that in Q4 of FY 2016. On an average the top ten Pharmaceutical companies by their market capitalization shelled out 17% of their revenues on R&D, whereas AstraZeneca proved to set the benchmark in this aspect as they spent just more than 25% of their revenues, this comes at a time when the total spending on R&D by the top 10 companies combined stood at $ 70 Billion in 2017 which has been stagnant for the past 5 to 6 years as the total spending of $ 70 Billion was spent in 2011 and 2012. In 2020, Astrazeneca’s R&D spending increased by 21% from their spending in 2019. The pharmacy company Roche invested the most overall but Astrazeneca saw the biggest jump in spending and it also invested the most as a percentage of their sales (24.8%).
The remaining section under "Strength" is available only in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
Complete Report
USD 12.53
- Debit/Credit card
- PayPal

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?



You may also be interested in other analyses of AstraZeneca:
-
AstraZeneca Porter's Five Forces Analysis -
AstraZeneca VRIO Analysis -
AstraZeneca Value Chain Analysis -
AstraZeneca Covid-19 Impact Analysis -
AstraZeneca BCG Analysis -
AstraZeneca Segmentation, Targeting and Positioning (STP) Analysis -
AstraZeneca Ansoff Matrix Analysis


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Check Out Analysis of Other Relevant Companies
References used in AstraZeneca SWOT & PESTLE Analysis Report
1. Annual Report - https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2020/pdf/AstraZeneca_AR_2020.pdf
2. Meet the most innovative and inventive pharmaceutical companies of 2021 - https://fortune.com/2021/04/16/top-pharmaceutical-companies-innovation-invention-2021/
3. India Rejects AstraZeneca Patent Appeal - https://www.industryweek.com/innovation/intellectual-property/article/21958985/india-rejects-astrazeneca-patent-appeal
4. Why does it cost so much to develop new drugs? - https://www.proclinical.com/blogs/2020-9/why-does-it-cost-so-much-to-develop-new-drugs
The detailed complete set of references are available on request in the 'Complete report' on purchase.
How to Reference This Page?
You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.
AstraZeneca SWOT & PESTLE Analysis - SWOT & PESTLE.COM
SWOT & PESTLE.com (2022). AstraZeneca SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/astrazeneca/ [Accessed 02 Jul, 2022].
In-text: (SWOT & PESTLE.com, 2022)
Copyrights and Disclaimer
AstraZeneca SWOT and PESTLE analysis has been conducted by Deepankar Pandey and reviewed by senior analysts from Barakaat Consulting.
Copyright of AstraZeneca SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.